Matches in SemOpenAlex for { <https://semopenalex.org/work/W968402012> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W968402012 abstract "OBJECTIVE/BACKGROUND:Positive treatment effects have been shown with Natalizumabin relapsing-remitting MS (RRMS) on physical disabilities, relapse rate and MRI detectable disease activity. Whereas cognitive deficits are common in MS (40-80[percnt]) only little is known about the effect of Natalizumab on cognition and depression. Therefore the present retrospective open label observational study investigates the effect of Natalizumab on attention and depression over a treatment period of two years.DESIGN/METHODS:51 patients with RRMS (male = 11, female = 40; mean age: 33.9+9.1 years) underwent a comprehensive neuropsychologicalassessment, consisting of different tests of attention (SDMT; Attention test battery: alertness, divided attention, flexibility), depression (CES-D) and fatigue (FSMC). The assessments are performed immediately before the first administration of Natalizumab, and again after one and two years of treatment.RESULTS:Significant improvements were found in 3 out of 10 attentionparameters after one year of treatment (SDMT: p = 0.02; alertness: reaction time (RT) cued, p = 0.02; divided attention: visual RT, p = 0.02) and in 5 out of 10 parameters in the second year of treatment (SDMT: p = 0.01; divided attention: visual RT: p = 0.000; errors, p = 0.01, omissions, p = 0.05; flexibility: RT, p = 0.05). The CES-D value decreased significantly in the first year from 29.41[percnt] of patients with depression to 21.56[percnt] (p = 0.047) and in the second year to 22.58[percnt] (p = 0.02) No effects were detected on fatigue.CONCLUSIONS:Our observational study has been able to show positive effects on attention parameters in patients with RRMS and, for the first time, reduced depression two years after treatment with Natalizumab.Study Supported by: Disclosure: Dr. Kunkel has nothing to disclose. Dr. Faiss has received personal compensation for activities with Biogen Idec, Schering, and Boehringer Ingelheim as a speaker. Dr. Koehler has received personal compensation for activities with Merck & Co. Inc., Bayer Pharmaceuticals Corp., Biogen Idec, Novartis, Genzyme, and Sanofi. Dr. Fischer has nothing to disclose." @default.
- W968402012 created "2016-06-24" @default.
- W968402012 creator A5028665311 @default.
- W968402012 creator A5064619581 @default.
- W968402012 creator A5084345895 @default.
- W968402012 creator A5091755989 @default.
- W968402012 date "2015-04-06" @default.
- W968402012 modified "2023-09-23" @default.
- W968402012 title "Improved cognition and depression in patients with MS after two years of treatment with Natalizumab (P3.275)" @default.
- W968402012 hasPublicationYear "2015" @default.
- W968402012 type Work @default.
- W968402012 sameAs 968402012 @default.
- W968402012 citedByCount "0" @default.
- W968402012 crossrefType "journal-article" @default.
- W968402012 hasAuthorship W968402012A5028665311 @default.
- W968402012 hasAuthorship W968402012A5064619581 @default.
- W968402012 hasAuthorship W968402012A5084345895 @default.
- W968402012 hasAuthorship W968402012A5091755989 @default.
- W968402012 hasConcept C118552586 @default.
- W968402012 hasConcept C126322002 @default.
- W968402012 hasConcept C139719470 @default.
- W968402012 hasConcept C14216870 @default.
- W968402012 hasConcept C15744967 @default.
- W968402012 hasConcept C162324750 @default.
- W968402012 hasConcept C169900460 @default.
- W968402012 hasConcept C200678441 @default.
- W968402012 hasConcept C23131810 @default.
- W968402012 hasConcept C2776867660 @default.
- W968402012 hasConcept C2780640218 @default.
- W968402012 hasConcept C2781004633 @default.
- W968402012 hasConcept C548259974 @default.
- W968402012 hasConcept C71924100 @default.
- W968402012 hasConceptScore W968402012C118552586 @default.
- W968402012 hasConceptScore W968402012C126322002 @default.
- W968402012 hasConceptScore W968402012C139719470 @default.
- W968402012 hasConceptScore W968402012C14216870 @default.
- W968402012 hasConceptScore W968402012C15744967 @default.
- W968402012 hasConceptScore W968402012C162324750 @default.
- W968402012 hasConceptScore W968402012C169900460 @default.
- W968402012 hasConceptScore W968402012C200678441 @default.
- W968402012 hasConceptScore W968402012C23131810 @default.
- W968402012 hasConceptScore W968402012C2776867660 @default.
- W968402012 hasConceptScore W968402012C2780640218 @default.
- W968402012 hasConceptScore W968402012C2781004633 @default.
- W968402012 hasConceptScore W968402012C548259974 @default.
- W968402012 hasConceptScore W968402012C71924100 @default.
- W968402012 hasOpenAccess W968402012 @default.
- W968402012 hasRelatedWork W1527192475 @default.
- W968402012 hasRelatedWork W1538583836 @default.
- W968402012 hasRelatedWork W1563337686 @default.
- W968402012 hasRelatedWork W1866017777 @default.
- W968402012 hasRelatedWork W2092686956 @default.
- W968402012 hasRelatedWork W2324794138 @default.
- W968402012 hasRelatedWork W2352039407 @default.
- W968402012 hasRelatedWork W2474667051 @default.
- W968402012 hasRelatedWork W2502219383 @default.
- W968402012 hasRelatedWork W2527470800 @default.
- W968402012 hasRelatedWork W2538400778 @default.
- W968402012 hasRelatedWork W2547541010 @default.
- W968402012 hasRelatedWork W2563551521 @default.
- W968402012 hasRelatedWork W2787707495 @default.
- W968402012 hasRelatedWork W2807914868 @default.
- W968402012 hasRelatedWork W2885221274 @default.
- W968402012 hasRelatedWork W643028323 @default.
- W968402012 hasRelatedWork W811949443 @default.
- W968402012 hasRelatedWork W1900569402 @default.
- W968402012 hasRelatedWork W204700027 @default.
- W968402012 hasVolume "84" @default.
- W968402012 isParatext "false" @default.
- W968402012 isRetracted "false" @default.
- W968402012 magId "968402012" @default.
- W968402012 workType "article" @default.